<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName journalpublishing.dtd?>
  <?SourceDTD.Version 2.3?>
  <?ConverterInfo.XSLTName jp2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Int J Nephrol Renovascular Dis</journal-id>
      <journal-title-group>
        <journal-title>International journal of nephrology and renovascular disease</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1178-7058</issn>
      <publisher>
        <publisher-name>Dove Medical Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3108794</article-id>
      <article-id pub-id-type="pmid">21694945</article-id>
      <article-id pub-id-type="doi">10.2147/IJNRD.S10233</article-id>
      <article-id pub-id-type="publisher-id">ijnrd-4-017</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Clearing the complexity: immune complexes and their treatment in lupus nephritis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Toong</surname>
            <given-names>Catherine</given-names>
          </name>
          <xref ref-type="aff" rid="af1-ijnrd-4-017">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Adelstein</surname>
            <given-names>Stephen</given-names>
          </name>
          <xref ref-type="aff" rid="af1-ijnrd-4-017">1</xref>
          <xref ref-type="corresp" rid="c1-ijnrd-4-017"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Phan</surname>
            <given-names>Tri Giang</given-names>
          </name>
          <xref ref-type="aff" rid="af2-ijnrd-4-017">2</xref>
          <xref ref-type="corresp" rid="c1-ijnrd-4-017"/>
        </contrib>
      </contrib-group>
      <aff id="af1-ijnrd-4-017"><label>1</label>Department of Clinical Immunology, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, Australia;</aff>
      <aff id="af2-ijnrd-4-017"><label>2</label>Immunology Program, Garvan Institute of Medical Research and St. Vincent&#x2019;s Clinical School, University of New South Wales, Darlinghurst, NSW, Australia</aff>
      <author-notes>
        <corresp id="c1-ijnrd-4-017">Correspondence: Stephen Adelstein, Department of Clinical Immunology, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050, Australia, Tel +61 2 95157585, Fax +61 2 95157762, Email <email>stephen.adelstein@sydney.edu.au</email> or Tri Giang Phan, Immunology Program, Garvan Institute of Medical Research and St. Vincent&#x2019;s, Clinical School, University of New South Wales, Darlinghurst NSW 2010, Australia, Tel +61 2 92958414, Fax +61 92958404, Email <email>t.phan@garvan.org.au</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>1</month>
        <year>2011</year>
      </pub-date>
      <volume>4</volume>
      <fpage>17</fpage>
      <lpage>28</lpage>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>1</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2011 Toong et al, publisher and licensee Dove Medical Press Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license>
          <license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Systemic lupus erythematosus (SLE) is a classic antibody-mediated systemic autoimmune disease characterised by the development of autoantibodies to ubiquitous self-antigens (such as antinuclear antibodies and antidouble-stranded DNA antibodies) and widespread deposition of immune complexes in affected tissues. Deposition of immune complexes in the kidney results in glomerular damage and occurs in all forms of lupus nephritis. The development of nephritis carries a poor prognosis and high risk of developing end-stage renal failure despite recent therapeutic advances. Here we review the role of DNA-anti-DNA immune complexes in the pathogenesis of lupus nephritis and possible new treatment strategies aimed at their control.</p>
      </abstract>
      <kwd-group>
        <kwd>immune complex</kwd>
        <kwd>systemic lupus erythematosus</kwd>
        <kwd>nephritis</kwd>
        <kwd>therapy</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="">
      <title>Introduction</title>
      <p>Systemic lupus erythematosus (SLE) is a complex, heterogeneous disease of multi-factorial etiology where multiple genetic, environmental and sex hormonal influences converge to break down B cell tolerance to self-antigens normally sequestered inside the cell nucleus.<xref ref-type="bibr" rid="b1-ijnrd-4-017">1</xref> Recent insights obtained from genetic mouse models and genome-wide association scans in large patient cohorts have enabled the identification of several key players in the multistep pathogenesis of lupus (<xref ref-type="fig" rid="f1-ijnrd-4-017">Figure 1</xref>). These studies reveal a positive feedback loop whereby inefficient clearance of apoptotic blebs by macrophages results in positive selection of germinal center B cells, which have self-reactivity against nuclear antigens exposed on these blebs. These self-reactive B cells undergo T cell-dependent affinity maturation and isotype switching,<xref ref-type="bibr" rid="b2-ijnrd-4-017">2</xref> and differentiate into long-lived plasma cells which reside in the bone marrow. The high affinity IgG anti-DNA antibodies secreted by these cells bind to the DNA to form immune complexes which activate plasmacytoid dendritic cells (pDCs) via toll-like receptor- (TLR-) 9 to produce inflammatory cytokines such as interferon-alpha. These cytokines augment the humoral immune response and lead to further autoantibody production. The high levels of circulating DNA-anti-DNA immune complexes overwhelm the capacity of the reticuloendothelial system (RES) to clear them, and they are deposited in various tissues including glomeruli where local complement activation results in glomerular injury.<xref ref-type="bibr" rid="b3-ijnrd-4-017">3</xref></p>
      <p>Nephritis is a common complication of SLE, occurring in 14% to 55% of patients, with higher rates seen in Asian, African, and Hispanic populations.<xref ref-type="bibr" rid="b4-ijnrd-4-017">4</xref> Histological patterns of lupus nephritis have been classified by the World Health Organization and, more recently, by the International Society of Nephrology/Renal Pathology Society (ISN/RPS) (<xref ref-type="table" rid="t1-ijnrd-4-017">Table 1</xref>).<xref ref-type="bibr" rid="b5-ijnrd-4-017">5</xref> These histologic patterns are predictive of prognosis<xref ref-type="bibr" rid="b6-ijnrd-4-017">6</xref> and provide a basis for treatment guidelines to prevent end-organ damage and improve mortality and morbidity. Despite improvements in the long-term survival of patients with SLE,<xref ref-type="bibr" rid="b7-ijnrd-4-017">7</xref> patients who develop nephritis still have a worse prognosis with a 10-year survival of only 88% compared with 94% for patients without nephritis.<xref ref-type="bibr" rid="b8-ijnrd-4-017">8</xref></p>
      <p>The mainstay of treatment for lupus nephritis has been corticosteroids, azathioprine, cyclophosphamide and, more recently, mycophenolate. These drugs are toxic with significant side effects and, despite their use, up to 20% of patients with nephritis will still progress to end-stage renal failure and require renal replacement therapy. It is timely therefore to re-examine the role of immune complexes in the pathogenesis of lupus nephritis and update the current status of new therapeutic strategies that target immune complexes.</p>
    </sec>
    <sec>
      <title>DNA-anti-DNA immune complexes in the pathogenesis of lupus nephritis</title>
      <p>Raised serum levels of circulating immune complexes have long been described in lupus, and correlate with disease activity.<xref ref-type="bibr" rid="b9-ijnrd-4-017">9</xref> The role of anti-DNA antibodies in lupus nephritis is also well documented, and the evidence for the involvement of complexes containing these autoantibodies is summarized in <xref ref-type="table" rid="t2-ijnrd-4-017">Table 2</xref>. Despite the evidence linking DNA-anti-DNA immune complexes to lupus nephritis, the precise mechanism of renal damage is still unknown. In the prevailing hypothesis, nucleosomes released from apoptotic cells bind to autoanti-bodies and deposit in glomeruli, resulting in complement activation and thus tissue injury. An alternative hypothesis is that anti-DNA antibodies cross-react with non-DNA components in glomeruli, but this is thought to be less likely.<xref ref-type="bibr" rid="b10-ijnrd-4-017">10</xref></p>
      <p>Doubts about the importance of DNA-anti-DNA immune complexes arise because not all patients with anti-DNA antibodies develop lupus nephritis. Furthermore, glomerular immune complex deposition may be seen without clinically overt renal disease,<xref ref-type="bibr" rid="b11-ijnrd-4-017">11</xref> suggesting that additional factors are necessary for the development of renal pathology. Particular characteristics of anti-DNA antibodies may make some more nephritogenic than others. For example, it has been postulated that the isotype and subclass of the antibody is important. In particular, the IgG isotype<xref ref-type="bibr" rid="b12-ijnrd-4-017">12</xref> and specifically the IgG3<xref ref-type="bibr" rid="b13-ijnrd-4-017">13</xref>,<xref ref-type="bibr" rid="b14-ijnrd-4-017">14</xref> or IgG2<xref ref-type="bibr" rid="b14-ijnrd-4-017">14</xref> subclasses present a higher risk of clinical nephritis. Although there is some evidence that avidity of anti-dsDNA antibodies may also play a role in vitro,<xref ref-type="bibr" rid="b15-ijnrd-4-017">15</xref>,<xref ref-type="bibr" rid="b16-ijnrd-4-017">16</xref> their role in vivo has been questioned.<xref ref-type="bibr" rid="b10-ijnrd-4-017">10</xref>,<xref ref-type="bibr" rid="b17-ijnrd-4-017">17</xref></p>
      <p>The specificity of anti-DNA antibodies is another important factor in pathogenicity. A specificity for nucleosomes rather than DNA,<xref ref-type="bibr" rid="b10-ijnrd-4-017">10</xref> the presence of cationic moieties that bind to negatively charged glycosaminoglycans such as heparan sulfate,<xref ref-type="bibr" rid="b18-ijnrd-4-017">18</xref> and cross-reactivity of antibodies with alpha-actinin<xref ref-type="bibr" rid="b19-ijnrd-4-017">19</xref> are linked to an increased likelihood of renal pathology. Consistent with the idea of immune complex-mediated damage being central to the pathogenesis of lupus nephritis, the availability of extra-cellular chromatin<xref ref-type="bibr" rid="b17-ijnrd-4-017">17</xref> has been identified as another factor linked to the development of nephritis. Abnormalities in DNA fragmentation as a result of reduced levels of the endonuclease DNase1 have been identified in mouse models of lupus nephritis, perhaps predisposing to the deposition of chromatin in glomeruli.<xref ref-type="bibr" rid="b20-ijnrd-4-017">20</xref></p>
      <p>Once DNA-anti-dsDNA immune complexes have been formed, they are normally cleared by the RES but defects of some of the clearance mechanisms have been described in SLE, including aberrant interactions with Fc&#x3B3; receptors (Fc&#x3B3;Rs), complement and complement receptors, and anti-C1q antibodies. With respect to the first of these interactions, a particular polymorphism in Fc&#x3B3;RIIB is associated with SLE in Asian populations.<xref ref-type="bibr" rid="b21-ijnrd-4-017">21</xref> Fc&#x3B3;RIIB has a cytoplasmic tail which mediates inhibitory functions. Therefore, Fc&#x3B3;RIIB signaling is important in controlling the immune response, and deficiency may predispose to autoimmunity.<xref ref-type="bibr" rid="b21-ijnrd-4-017">21</xref> The activating Fc&#x3B3;Rs are also involved in the pathogenesis of lupus nephritis. Immune complex binding to Fc&#x3B3;RI and Fc&#x3B3;RIII trigger monocytes and macrophages to release proinflammatory mediators and chemokines which recruit immune effector cells that contribute to renal damage.<xref ref-type="bibr" rid="b22-ijnrd-4-017">22</xref>&#x2013;<xref ref-type="bibr" rid="b24-ijnrd-4-017">24</xref> Increased expression of Fc&#x3B3;RI on monocytes has been found to correlate with the presence of active lupus nephritis.<xref ref-type="bibr" rid="b23-ijnrd-4-017">23</xref> Secondly, genetic variations in C4 can affect the handling of immune complexes. Deficiency in C4A relative to C4B is common in SLE, and has also been associated with the development of lupus nephritis. C4A prevents immune complex precipitation, and therefore deficiency could result in increased deposition. A number of other variants of C4 may promote or protect against immune complex damage.<xref ref-type="bibr" rid="b25-ijnrd-4-017">25</xref> Thirdly, immune complexes that bind and activate complement can also be cleared by high affinity complement binding receptor type 1 (CR1, CD35). SLE patients have reduced expression of CR1 on their erythrocytes, perhaps contributing to defective clearance of immune complexes.<xref ref-type="bibr" rid="b26-ijnrd-4-017">26</xref> Fourthly, the presence of anti-C1q antibodies can influence the handling of immune complexes. These autoantibodies have been associated with the presence and activity of lupus nephritis.<xref ref-type="bibr" rid="b27-ijnrd-4-017">27</xref>,<xref ref-type="bibr" rid="b28-ijnrd-4-017">28</xref> Infusion of anti-C1q antibodies results in deposition in glomeruli in mice, which are not pathogenic unless C1q-fixing antiglomerular basement membrane antibodies (at subnephritogenic doses) are also present.<xref ref-type="bibr" rid="b29-ijnrd-4-017">29</xref> It is thought that anti-C1q antibodies amplify the complement cascade by themselves fixing and activating complement, recruiting further anti-C1q antibodies, and thus increasing the risk of renal damage.</p>
      <p>Immune complexes containing DNA signal via TLR-9 and can activate plasmacytoid dendritic cells,<xref ref-type="bibr" rid="b30-ijnrd-4-017">30</xref> which then process and present chromatin-derived peptides to costimulate T helper cells. Chromatin-specific T cells interact with dsDNA-specific B cells, facilitating the secretion of anti-DNA antibodies. Renal damage results from a combination of complement activation and cellular inflammation. A Th1 response is associated with diffuse proliferative lupus nephritis, while a Th2 response is associated with the membranous form.<xref ref-type="bibr" rid="b31-ijnrd-4-017">31</xref> Thrombotic microangiopathy caused by antiphospholipid antibodies may also contribute to the final pathology.</p>
    </sec>
    <sec>
      <title>Therapies of lupus nephritis targeting immune complex formation</title>
      <p>The mainstays of treatment of lupus nephritis are corticosteroid therapy combined with cyclophosphamide or mycophenolate for induction therapy, and corticosteroids combined with azathioprine or mycophenolate for maintenance therapy. The evidence for the use of these agents is summarized in <xref ref-type="table" rid="t3-ijnrd-4-017">Tables 3</xref> and <xref ref-type="table" rid="t4-ijnrd-4-017">4</xref>. These agents are not specifically targeted at the reduction of DNA-anti-DNA immune complexes per se. However, a reduction in autoantibody formation and hence immune complex generation occurs after the broad immunosuppression caused by these agents, and a decrease in serum anti-dsDNA antibody levels accompanied clinical improvement in most studies listed.</p>
      <p>Specific strategies for targeting immune complex formation include: reducing autoantibody production (targeting B cells), reducing the binding of autoantibodies, reducing the availability of nucleosomal material, increasing the clearance of immune complexes, and interfering in the feedback loop (<xref ref-type="fig" rid="f1-ijnrd-4-017">Figure 1</xref>). This is a theoretical framework, and while the mechanisms of action of some of the currently used treatments for lupus nephritis may fall into these categories, further research is necessary in each of these areas to understand their mechanisms and potential clinical efficacy.</p>
      <sec>
        <title>Reducing autoantibody production (targeting B cells and plasma cells)</title>
        <p>Theoretically, autoantibody production may be reduced by depletion of B cells (either by targeting B cell surface molecules or by removing factors required for B cell survival); interfering with the development or function of plasma cells; or by inducing B-cell tolerance.</p>
        <sec>
          <title>B cell depletion</title>
          <p>Anti-nucleosome and anti-dsDNA antibodies are modestly reduced by anti-CD20 mAbs such as rituximab, which effect B cell depletion. The reduction in these titers suggests that these autoantibodies are produced by a B cell population with more rapid turnover than cells that produce anti-ENA, anti-tetanus or antipneumococcal antibodies, which persist. However, their incomplete reduction may reflect the presence of longer-lived plasma cells which do not express CD20.<xref ref-type="bibr" rid="b32-ijnrd-4-017">32</xref> Trials of rituximab, however, have yielded conflicting results on clinical endpoints (see <xref ref-type="table" rid="t3-ijnrd-4-017">Table 3</xref>). Uncontrolled, observational, and retrospective studies seemed to demonstrate benefit in lupus nephritis, but two major randomized trials failed to find benefit. The LUpus Nephritis Assessment with Rituximab (LUNAR) trial, which specifically included patients with proliferative lupus nephritis, did not demonstrate any difference in the proportion of patients obtaining a renal response to rituximab compared with placebo.<xref ref-type="bibr" rid="b33-ijnrd-4-017">33</xref> However, the use of mycophenolate rather than cyclophosphamide as background therapy in this trial has been criticized, as it is thought that the effects of rituximab may be enhanced, or synergistic, with cyclophosphamide.<xref ref-type="bibr" rid="b34-ijnrd-4-017">34</xref> Further, given that all participants were treated with mycophenolate, any effect of rituximab may have been masked. The other major trial, Rituximab in patients with Severe Systemic Lupus Erythematosus (EXPLORER),<xref ref-type="bibr" rid="b35-ijnrd-4-017">35</xref> excluded major organ threatening disease and thus &lt;2% of the patients had renal involvement. This trial found no difference in the rituximab compared with placebo-treated groups, but given its patient characteristics, this finding cannot be applied to patients with lupus nephritis. Contrary to these findings, prospective follow-up of 31 patients with lupus nephritis from a cohort of 136 patients entered in the French Autoimmunity and Rituximab registry,<xref ref-type="bibr" rid="b36-ijnrd-4-017">36</xref> demonstrated renal response in 74% of patients, with complete response in 45%. Unfortunately, trials of another anti-CD20 agent, ocrelizumab (BELONG), for lupus nephritis have been halted due to concerns over serious and opportunistic infections.<xref ref-type="bibr" rid="b37-ijnrd-4-017">37</xref></p>
          <p>A plethora of other anti-B cell therapies is on the horizon, targeting all aspects important for B cell existence and function, such as survival factors, differentiation factors, co-stimulatory factors, cell-signaling pathways, and homing factors.<xref ref-type="bibr" rid="b38-ijnrd-4-017">38</xref> Most of these studies are in preliminary phases, or have not been evaluated in human lupus nephritis. Belimumab, a fully human recombinant monoclonal antibody that binds to and inhibits B lymphocyte stimulator (BLyS, also known as B cell activating factor or BAFF) has been shown to reduce anti-dsDNA titers by 29%, but patients with lupus nephritis were excluded from early trials.<xref ref-type="bibr" rid="b39-ijnrd-4-017">39</xref>,<xref ref-type="bibr" rid="b40-ijnrd-4-017">40</xref> More recently, the large phase III studies, BLISS-52 and BLISS-76, have shown promise with improvements in the SLE responder index, though more information on lupus nephritis and belimumab is awaited. The Food and Drug Administration has granted this drug a priority review designation as a potential treatment for SLE (GSK press release August 19, 2010). Epratuzumab, targets CD22, a surface molecule involved in regulating B cell receptor signaling, and modifies B cell function. A phase II study has had promising results, with improvements in BILAG scores despite lack of reduction in anti-dsDNA levels, although there were too few patients with lupus nephritis to draw any conclusions about efficacy in this domain.<xref ref-type="bibr" rid="b41-ijnrd-4-017">41</xref></p>
        </sec>
        <sec>
          <title>Targeting plasma cells</title>
          <p>If B cell depletion does indeed reduce immune complexes it may do so indirectly by killing the precursor germinal center B cells that give rise to antibody-secreting plasma cells. To reduce autoantibody production more effectively, agents targeting plasma cells specifically may be more useful. Indeed, corticosteroids may well exert their beneficial effect by this mechanism, among others. Proteasome inhibitors have been introduced into the therapeutic armamentarium for multiple myeloma due to their ability to cause apoptosis of plasma cells.<xref ref-type="bibr" rid="b42-ijnrd-4-017">42</xref> The use of proteasome inhibitors in SLE has been promising in mouse models, eliminating autoreactive plasma cells, reducing anti-dsDNA antibody levels, and preventing nephritis;<xref ref-type="bibr" rid="b43-ijnrd-4-017">43</xref> human trials are underway.</p>
        </sec>
        <sec>
          <title>Induction of B cell tolerance</title>
          <p>Induction of tolerance would be the ultimate way to reduce anti-dsDNA antibody concentrations. Although murine models have provided hope, human trials have again been unimpressive. Regular injections of nucleosomal peptide autoepitopes in lupus-prone mice reduced autoantibody levels and delayed the onset of nephritis by the induction of TGF-producing regulatory T cells.<xref ref-type="bibr" rid="b44-ijnrd-4-017">44</xref> However, abetimus, a conjugate composed of 4 identical strands of dsDNA, did not show any benefit in reducing renal flares in human SLE. Interestingly, abetimus did reduce the level of anti-dsDNA antibodies, possibly due to the formation of soluble complexes that were rapidly eliminated and, possibly, by tolerizing B cells and reducing autoantibody production.<xref ref-type="bibr" rid="b45-ijnrd-4-017">45</xref></p>
        </sec>
      </sec>
      <sec>
        <title>Reducing the binding of autoantibodies</title>
        <p>The mechanism of action of the antimalarials chloroquine and hydroxychloroquine in SLE has recently been revisited, because of the recognition of their inhibition of TLR-9 binding to DNA, by preventing acidification of the lysosome. However, hydroxychloroquine, as one of its many mechanisms of action, also affects the affinity of binding of antibodies to their targets. Hydroxychloroquine interferes with the binding of antiphospholipid antibodies in vitro, and causes a reduction in the levels of these autoantibodies as measured by commercially available ELISAs.<xref ref-type="bibr" rid="b46-ijnrd-4-017">46</xref> We recently demonstrated that the binding of anti-dsDNA antibodies as measured by the modified Farr assay is reduced by the addition of hydroxychloroquine in vitro.<xref ref-type="bibr" rid="b47-ijnrd-4-017">47</xref> This effect is likely to be due to the high protein-binding capacity of hydroxychloroquine,<xref ref-type="bibr" rid="b48-ijnrd-4-017">48</xref> and intercalation of DNA (if sharing this property with chloroquine),<xref ref-type="bibr" rid="b49-ijnrd-4-017">49</xref>,<xref ref-type="bibr" rid="b50-ijnrd-4-017">50</xref> potentially modifying critical autoepitopes. Whether this affects the pathogenesis of human lupus nephritis is unknown.</p>
      </sec>
      <sec>
        <title>Reducing the availability of DNA and nucleosomal material</title>
        <p>Material for anti-dsDNA and antinucleosome antibodies to bind may originate from tissue damage in the kidneys, resulting in situ formation of complexes or, alternatively, from damage remotely, resulting in the formation of circulating immune complexes, which then deposit in glomeruli (reviewed by Fismen et al<xref ref-type="bibr" rid="b51-ijnrd-4-017">51</xref>). A phase Ib trial of recombinant human DNase I (rhDNase) to hydrolyze extracellular DNA in patients with lupus did not reduce anti-dsDNA levels, the concentrations of circulating immune complexes, nor change other serological markers.<xref ref-type="bibr" rid="b52-ijnrd-4-017">52</xref> No further studies of rhDNase have been published.</p>
      </sec>
      <sec>
        <title>Increasing the clearance of immune complexes</title>
        <p>Plasmapheresis is able to lower the titer of anti-dsDNA antibodies but does not necessarily result in sustained clinical remission once withdrawn, possibly due to compensatory increased production by pathogenic B cell clones (rebound effect).<xref ref-type="bibr" rid="b53-ijnrd-4-017">53</xref> Removal of pathogenic anti-dsDNA antibodies physically by plasmapheresis may improve outcomes for those receiving intravenous (IV) cyclophosphamide. A combination of plasmapheresis and IV cyclophosphamide results in higher rates of complete renal remission than IV cyclophosphamide alone.<xref ref-type="bibr" rid="b54-ijnrd-4-017">54</xref>,<xref ref-type="bibr" rid="b55-ijnrd-4-017">55</xref> However, not all trials have found benefit, and larger randomized trials are required to confirm these findings. Other small studies and case reports have also demonstrated benefit with immunoadsorption plasmapheresis,<xref ref-type="bibr" rid="b56-ijnrd-4-017">56</xref>,<xref ref-type="bibr" rid="b57-ijnrd-4-017">57</xref> but further investigation is required to clarify the role of this treatment.</p>
      </sec>
      <sec>
        <title>Breaking the feedback (amplification) loop</title>
        <p>Signaling of immune complexes containing RNA and DNA via TLRs 7 and 9, respectively, activates plasmacytoid dendritic cells to produce large amounts of type I interferon. Type I interferons activate B cells and enhance antibody responses to soluble proteins, thereby completing a feedback loop resulting in the increased production of immune complexes.<xref ref-type="bibr" rid="b58-ijnrd-4-017">58</xref> One of the mechanisms of action for antimalarial drugs such as hydroxychloroquine in lupus is thought to be the inhibition of nucleic acid interaction with intracellular TLRs 7 and 9, possibly as a result of an increase in pH in microsomal compartments.<xref ref-type="bibr" rid="b59-ijnrd-4-017">59</xref> Novel treatments aimed at blocking TLR7 and TLR9 are being developed.<xref ref-type="bibr" rid="b60-ijnrd-4-017">60</xref> A phase I study of an anti-interferon-&#x3B1; monoclonal antibody has been completed,<xref ref-type="bibr" rid="b61-ijnrd-4-017">61</xref> and a phase II study is underway.</p>
      </sec>
    </sec>
    <sec>
      <title>Conclusion</title>
      <p>Immune complexes containing IgG anti-dsDNA antibodies and DNA play a significant role in the complex pathogenesis of lupus nephritis. Although strategies specifically aimed at reducing immune complexes in SLE are mostly novel, they provide a fertile area for further research. Disappointments with early trials of new therapeutics strengthen the argument that a combination of strategies aimed at different pathogenic mechanisms is likely to be necessary to improve the prognosis of this disease.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Disclosure</bold>
        </p>
        <p>The authors report no conflicts of interest.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="b1-ijnrd-4-017">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rahman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Isenberg</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of disease: systemic lupus erythematosus</article-title>
          <source>N Engl J Med</source>
          <year>2008</year>
          <volume>358</volume>
          <fpage>929</fpage>
          <lpage>939</lpage>
          <pub-id pub-id-type="pmid">18305268</pub-id>
        </element-citation>
      </ref>
      <ref id="b2-ijnrd-4-017">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Radic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marion</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Monestier</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Nucleosomes are exposed at the cell surface in apoptosis</article-title>
          <source>J Immunol</source>
          <year>2004</year>
          <volume>172</volume>
          <fpage>6692</fpage>
          <lpage>6700</lpage>
          <pub-id pub-id-type="pmid">15153485</pub-id>
        </element-citation>
      </ref>
      <ref id="b3-ijnrd-4-017">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Biesecker</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Katz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Koffler</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis</article-title>
          <source>J Exp Med</source>
          <year>1981</year>
          <volume>154</volume>
          <fpage>1779</fpage>
          <lpage>1794</lpage>
          <pub-id pub-id-type="pmid">7033435</pub-id>
        </element-citation>
      </ref>
      <ref id="b4-ijnrd-4-017">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ortega</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Schultz</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Lenz</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lupus nephritis: pathologic features, epidemiology, and a guide to therapeutic decisions</article-title>
          <source>Lupus</source>
          <year>2010</year>
          <volume>19</volume>
          <fpage>557</fpage>
          <lpage>574</lpage>
          <pub-id pub-id-type="pmid">20089610</pub-id>
        </element-citation>
      </ref>
      <ref id="b5-ijnrd-4-017">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weening</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>D&#x2019;Agati</surname>
              <given-names>VD</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>MM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The classification of glomerulonephritis in systemic lupus erythematosus revisited</article-title>
          <source>Kidney Int</source>
          <year>2004</year>
          <volume>65</volume>
          <fpage>521</fpage>
          <lpage>530</lpage>
          <pub-id pub-id-type="pmid">14717922</pub-id>
        </element-citation>
      </ref>
      <ref id="b6-ijnrd-4-017">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Najafi</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Korbet</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>EJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis</article-title>
          <source>Kidney Int</source>
          <year>2001</year>
          <volume>59</volume>
          <fpage>2156</fpage>
          <lpage>2163</lpage>
          <pub-id pub-id-type="pmid">11380817</pub-id>
        </element-citation>
      </ref>
      <ref id="b7-ijnrd-4-017">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borchers</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Keen</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Shoenfeld</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus</article-title>
          <source>Autoimmun Rev</source>
          <year>2004</year>
          <volume>3</volume>
          <fpage>423</fpage>
          <lpage>453</lpage>
          <pub-id pub-id-type="pmid">15351310</pub-id>
        </element-citation>
      </ref>
      <ref id="b8-ijnrd-4-017">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cervera</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Khamashta</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Font</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients</article-title>
          <source>Medicine (Baltimore)</source>
          <year>2003</year>
          <volume>82</volume>
          <fpage>299</fpage>
          <lpage>308</lpage>
          <pub-id pub-id-type="pmid">14530779</pub-id>
        </element-citation>
      </ref>
      <ref id="b9-ijnrd-4-017">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levinsky</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Cameron</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Soothill</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Serum immune complexes and disease activity in lupus nephritis</article-title>
          <source>Lancet</source>
          <year>1977</year>
          <volume>1</volume>
          <fpage>564</fpage>
          <lpage>567</lpage>
          <pub-id pub-id-type="pmid">65659</pub-id>
        </element-citation>
      </ref>
      <ref id="b10-ijnrd-4-017">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mortensen</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Rekvig</surname>
              <given-names>OP</given-names>
            </name>
          </person-group>
          <article-title>Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2009</year>
          <volume>20</volume>
          <fpage>696</fpage>
          <lpage>704</lpage>
          <pub-id pub-id-type="pmid">19329762</pub-id>
        </element-citation>
      </ref>
      <ref id="b11-ijnrd-4-017">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cruchaud</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chenais</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Fournie</surname>
              <given-names>GJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Immune complex deposits in systemic lupus erythematosus kidney without histological or functional alterations</article-title>
          <source>Eur J Clin Invest</source>
          <year>1975</year>
          <volume>1975</volume>
          <fpage>297</fpage>
          <lpage>309</lpage>
          <pub-id pub-id-type="pmid">1149788</pub-id>
        </element-citation>
      </ref>
      <ref id="b12-ijnrd-4-017">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Forger</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Matthias</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Oppermann</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis</article-title>
          <source>Lupus</source>
          <year>2004</year>
          <volume>13</volume>
          <fpage>36</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="pmid">14870916</pub-id>
        </element-citation>
      </ref>
      <ref id="b13-ijnrd-4-017">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amoura</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Koutouzov</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chabre</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus</article-title>
          <source>Arthritis Rheum</source>
          <year>2000</year>
          <volume>43</volume>
          <fpage>76</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="pmid">10643702</pub-id>
        </element-citation>
      </ref>
      <ref id="b14-ijnrd-4-017">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bijl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dijstelbloem</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Oost</surname>
              <given-names>WW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2002</year>
          <volume>41</volume>
          <fpage>62</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="pmid">11792881</pub-id>
        </element-citation>
      </ref>
      <ref id="b15-ijnrd-4-017">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Villalta</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Romelli</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Savina</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-dsDNA antibody avidity determination by a simple reliable ELISA method for SLE diagnosis and monitoring</article-title>
          <source>Lupus</source>
          <year>2003</year>
          <volume>12</volume>
          <fpage>31</fpage>
          <lpage>36</lpage>
          <pub-id pub-id-type="pmid">12587824</pub-id>
        </element-citation>
      </ref>
      <ref id="b16-ijnrd-4-017">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jaekel</surname>
              <given-names>H-P</given-names>
            </name>
            <name>
              <surname>Trabandt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grobe</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis</article-title>
          <source>Lupus</source>
          <year>2006</year>
          <volume>15</volume>
          <fpage>335</fpage>
          <lpage>345</lpage>
          <pub-id pub-id-type="pmid">16830879</pub-id>
        </element-citation>
      </ref>
      <ref id="b17-ijnrd-4-017">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fenton</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Tommeras</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Marion</surname>
              <given-names>TN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice</article-title>
          <source>Autoimmunity</source>
          <year>2010</year>
          <volume>43</volume>
          <fpage>179</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="pmid">19835488</pub-id>
        </element-citation>
      </ref>
      <ref id="b18-ijnrd-4-017">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kohro-Kawata</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kawata</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Highly cationic anti-DNA antibodies in patients with lupus nephritis analyzed by two-dimensional electrophoresis and immunoblotting</article-title>
          <source>Electrophoresis</source>
          <year>1998</year>
          <volume>19</volume>
          <fpage>1511</fpage>
          <lpage>1515</lpage>
          <pub-id pub-id-type="pmid">9694304</pub-id>
        </element-citation>
      </ref>
      <ref id="b19-ijnrd-4-017">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mostoslavsky</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fischel</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Yachimovich</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry</article-title>
          <source>Eur J Immunol</source>
          <year>2001</year>
          <volume>31</volume>
          <fpage>1221</fpage>
          <lpage>1227</lpage>
          <pub-id pub-id-type="pmid">11298348</pub-id>
        </element-citation>
      </ref>
      <ref id="b20-ijnrd-4-017">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zykova</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Seredkina</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Benjaminsen</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reduced fragmentation of apoptotic chromatin is associated with nephritis in lupus-prone (NZB x NZW)F(1) mice</article-title>
          <source>Arthritis Rheum</source>
          <year>2008</year>
          <volume>58</volume>
          <fpage>813</fpage>
          <lpage>825</lpage>
          <pub-id pub-id-type="pmid">18311834</pub-id>
        </element-citation>
      </ref>
      <ref id="b21-ijnrd-4-017">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Ji</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>GG</given-names>
            </name>
          </person-group>
          <article-title>Fcgamma receptor IIB and IIIB polymorphisms and susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis</article-title>
          <source>Lupus</source>
          <year>2009</year>
          <volume>18</volume>
          <issue>8</issue>
          <fpage>727</fpage>
          <lpage>734</lpage>
          <pub-id pub-id-type="pmid">19502269</pub-id>
        </element-citation>
      </ref>
      <ref id="b22-ijnrd-4-017">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bergtold</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gavhane</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>D&#x2019;Agati</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis</article-title>
          <source>J Immunol</source>
          <year>2006</year>
          <volume>177</volume>
          <fpage>7287</fpage>
          <lpage>7295</lpage>
          <pub-id pub-id-type="pmid">17082647</pub-id>
        </element-citation>
      </ref>
      <ref id="b23-ijnrd-4-017">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>PY</given-names>
            </name>
            <name>
              <surname>Sobel</surname>
              <given-names>ES</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased expression of Fc&#x3B3;RI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus</article-title>
          <source>Arthritis Res Ther</source>
          <year>2009</year>
          <volume>11</volume>
          <fpage>R6</fpage>
          <pub-id pub-id-type="pmid">19144150</pub-id>
        </element-citation>
      </ref>
      <ref id="b24-ijnrd-4-017">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clynes</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Calvani</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Croker</surname>
              <given-names>BP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Modulation of immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors</article-title>
          <source>Clin Exp Immunol</source>
          <year>2005</year>
          <volume>141</volume>
          <fpage>230</fpage>
          <lpage>237</lpage>
          <pub-id pub-id-type="pmid">15996187</pub-id>
        </element-citation>
      </ref>
      <ref id="b25-ijnrd-4-017">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karp</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Complement and systemic lupus erythematosus</article-title>
          <source>Curr Opin Rheumatol</source>
          <year>2005</year>
          <volume>17</volume>
          <fpage>538</fpage>
          <lpage>542</lpage>
          <pub-id pub-id-type="pmid">16093830</pub-id>
        </element-citation>
      </ref>
      <ref id="b26-ijnrd-4-017">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kavai</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Immune complex clearance by complement receptor type 1 in SLE</article-title>
          <source>Autoimmun Rev</source>
          <year>2008</year>
          <volume>8</volume>
          <fpage>160</fpage>
          <lpage>164</lpage>
          <pub-id pub-id-type="pmid">18602499</pub-id>
        </element-citation>
      </ref>
      <ref id="b27-ijnrd-4-017">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sinico</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Ikehata</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Giammarresi</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance</article-title>
          <source>Ann N Y Acad Sci</source>
          <year>2005</year>
          <volume>1050</volume>
          <fpage>193</fpage>
          <lpage>200</lpage>
          <pub-id pub-id-type="pmid">16014534</pub-id>
        </element-citation>
      </ref>
      <ref id="b28-ijnrd-4-017">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trendelenburg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lopez-Trascasa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Potlukova</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis</article-title>
          <source>Nephrol Dial Transplant</source>
          <year>2006</year>
          <volume>21</volume>
          <fpage>3115</fpage>
          <lpage>3121</lpage>
          <pub-id pub-id-type="pmid">16877491</pub-id>
        </element-citation>
      </ref>
      <ref id="b29-ijnrd-4-017">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trouw</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Groeneveld</surname>
              <given-names>TWL</given-names>
            </name>
            <name>
              <surname>Seelen</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-C1q autoantibodies desposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes</article-title>
          <source>J Clin Invest</source>
          <year>2004</year>
          <volume>114</volume>
          <fpage>679</fpage>
          <lpage>688</lpage>
          <pub-id pub-id-type="pmid">15343386</pub-id>
        </element-citation>
      </ref>
      <ref id="b30-ijnrd-4-017">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boule</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Broughton</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mackay</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes</article-title>
          <source>J Exp Med</source>
          <year>2004</year>
          <volume>199</volume>
          <fpage>1631</fpage>
          <lpage>1640</lpage>
          <pub-id pub-id-type="pmid">15197227</pub-id>
        </element-citation>
      </ref>
      <ref id="b31-ijnrd-4-017">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaveri</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Mouthon</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bayry</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Basophils and nephritis in lupus</article-title>
          <source>N Engl J Med</source>
          <year>2010</year>
          <volume>363</volume>
          <fpage>1080</fpage>
          <lpage>1082</lpage>
          <pub-id pub-id-type="pmid">20825323</pub-id>
        </element-citation>
      </ref>
      <ref id="b32-ijnrd-4-017">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cambridge</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Leandro</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Teodorescu</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles</article-title>
          <source>Arthritis Rheum</source>
          <year>2006</year>
          <volume>54</volume>
          <fpage>3612</fpage>
          <lpage>3622</lpage>
          <pub-id pub-id-type="pmid">17075806</pub-id>
        </element-citation>
      </ref>
      <ref id="b33-ijnrd-4-017">
        <label>33.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="editor">
            <name>
              <surname>Furie</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Looney</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rovin</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy and safety of ritux-imab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study</article-title>
          <conf-name>American College of Rheumatology National Meeting 2009</conf-name>
          <conf-loc>Philadelphia (PA)</conf-loc>
          <conf-date>2009 Oct 17&#x2013;21</conf-date>
          <comment>Abstract 1149.</comment>
        </element-citation>
      </ref>
      <ref id="b34-ijnrd-4-017">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Looney</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data</article-title>
          <source>Drugs</source>
          <year>2010</year>
          <volume>70</volume>
          <fpage>529</fpage>
          <lpage>540</lpage>
          <pub-id pub-id-type="pmid">20297867</pub-id>
        </element-citation>
      </ref>
      <ref id="b35-ijnrd-4-017">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Merrill</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Neuwelt</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Wallace</surname>
              <given-names>DJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial</article-title>
          <source>Arthritis Rheum</source>
          <volume>62</volume>
          <fpage>222</fpage>
          <lpage>233</lpage>
          <pub-id pub-id-type="pmid">20039413</pub-id>
        </element-citation>
      </ref>
      <ref id="b36-ijnrd-4-017">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Terrier</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Amoura</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Ravaud</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry</article-title>
          <source>Arthritis Rheum</source>
          <volume>62</volume>
          <fpage>2458</fpage>
          <lpage>2466</lpage>
          <pub-id pub-id-type="pmid">20506527</pub-id>
        </element-citation>
      </ref>
      <ref id="b37-ijnrd-4-017">
        <label>37.</label>
        <element-citation publication-type="book">
          <article-title>Roche and Biogen Idec decide to suspend ocrelizumab treatment &#x2013; rheumatoid arthritis development programme on hold</article-title>
          <publisher-name>Biogen Idec</publisher-name>
          <year>2010</year>
          <comment><ext-link ext-link-type="uri" xlink:href="http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&amp;ReqId=1400446">http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&amp;ReqId=1400446</ext-link>. Accessed 2010 Oct 12.</comment>
        </element-citation>
      </ref>
      <ref id="b38-ijnrd-4-017">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>FE</given-names>
            </name>
          </person-group>
          <article-title>B cells as therapeutic targets in SLE</article-title>
          <source>Nat Rev Rheumatol</source>
          <year>2010</year>
          <volume>6</volume>
          <fpage>326</fpage>
          <lpage>337</lpage>
          <pub-id pub-id-type="pmid">20520647</pub-id>
        </element-citation>
      </ref>
      <ref id="b39-ijnrd-4-017">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wallace</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Stohl</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Furie</surname>
              <given-names>RA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus</article-title>
          <source>Arthritis Care Res</source>
          <year>2009</year>
          <volume>61</volume>
          <fpage>1168</fpage>
          <lpage>1178</lpage>
        </element-citation>
      </ref>
      <ref id="b40-ijnrd-4-017">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jacobi</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study</article-title>
          <source>Arthritis Rheum</source>
          <year>2010</year>
          <volume>62</volume>
          <fpage>201</fpage>
          <lpage>210</lpage>
          <pub-id pub-id-type="pmid">20039404</pub-id>
        </element-citation>
      </ref>
      <ref id="b41-ijnrd-4-017">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dorner</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wegener</surname>
              <given-names>WA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus</article-title>
          <source>Arthritis Res Ther</source>
          <year>2006</year>
          <volume>8</volume>
          <fpage>R74</fpage>
          <pub-id pub-id-type="pmid">16630358</pub-id>
        </element-citation>
      </ref>
      <ref id="b42-ijnrd-4-017">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dingli</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rajkumar</surname>
              <given-names>SV</given-names>
            </name>
          </person-group>
          <article-title>How best to use new therapies in multiple myeloma</article-title>
          <source>Blood Rev</source>
          <year>2010</year>
          <volume>24</volume>
          <fpage>91</fpage>
          <lpage>100</lpage>
          <pub-id pub-id-type="pmid">20359801</pub-id>
        </element-citation>
      </ref>
      <ref id="b43-ijnrd-4-017">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neubert</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Meister</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Moser</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis</article-title>
          <source>Nat Med</source>
          <year>2008</year>
          <volume>14</volume>
          <fpage>748</fpage>
          <lpage>755</lpage>
          <pub-id pub-id-type="pmid">18542049</pub-id>
        </element-citation>
      </ref>
      <ref id="b44-ijnrd-4-017">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kang</surname>
              <given-names>H-K</given-names>
            </name>
            <name>
              <surname>Michaels</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Berner</surname>
              <given-names>BR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Very low-dose tolerance with nucleosomal peptides controls lupus and induces regulatory T cell subsets</article-title>
          <source>J Immunol</source>
          <year>2005</year>
          <volume>174</volume>
          <fpage>3247</fpage>
          <lpage>3255</lpage>
          <pub-id pub-id-type="pmid">15749855</pub-id>
        </element-citation>
      </ref>
      <ref id="b45-ijnrd-4-017">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cardiel</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Tumlin</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Furie</surname>
              <given-names>RA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial</article-title>
          <source>Arthritis Rheum</source>
          <year>2008</year>
          <volume>58</volume>
          <fpage>2470</fpage>
          <lpage>2480</lpage>
          <pub-id pub-id-type="pmid">18668592</pub-id>
        </element-citation>
      </ref>
      <ref id="b46-ijnrd-4-017">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rand</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>X-X</given-names>
            </name>
            <name>
              <surname>Quinn</surname>
              <given-names>AS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-&#x3B2;2-glycoprotein I complexes to phospholipid bilayers</article-title>
          <source>Blood</source>
          <year>2008</year>
          <volume>112</volume>
          <fpage>1687</fpage>
          <lpage>1695</lpage>
          <pub-id pub-id-type="pmid">18577708</pub-id>
        </element-citation>
      </ref>
      <ref id="b47-ijnrd-4-017">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Toong</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wienholt</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Adelstein</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Hydroxychloroquine reduces binding of anti-double stranded DNA antibodies in vitro</article-title>
          <source>Intern Med J</source>
          <year>2010</year>
          <volume>40</volume>
          <issue>Suppl 4</issue>
          <fpage>17</fpage>
        </element-citation>
      </ref>
      <ref id="b48-ijnrd-4-017">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McLachlan</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Cutler</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Tett</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
          <article-title>Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites</article-title>
          <source>Eur J Clin Pharmacol</source>
          <year>1993</year>
          <volume>44</volume>
          <fpage>481</fpage>
          <lpage>484</lpage>
          <pub-id pub-id-type="pmid">8359187</pub-id>
        </element-citation>
      </ref>
      <ref id="b49-ijnrd-4-017">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scaria</surname>
              <given-names>PV</given-names>
            </name>
            <name>
              <surname>Craig</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Shafer</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Differential binding of the enantiomers of chloroquine and quinacrine to polynucleotides: implications for stereoselective metabolism</article-title>
          <source>Biopolymers</source>
          <year>1993</year>
          <volume>33</volume>
          <fpage>887</fpage>
          <lpage>895</lpage>
          <pub-id pub-id-type="pmid">8318663</pub-id>
        </element-citation>
      </ref>
      <ref id="b50-ijnrd-4-017">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwakye-Berko</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Meshnick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Sequence preference of chloroquine binding to DNA and prevention of Z-DNA formation</article-title>
          <source>Mol Biochem Paristol</source>
          <year>1990</year>
          <volume>39</volume>
          <fpage>275</fpage>
          <lpage>278</lpage>
        </element-citation>
      </ref>
      <ref id="b51-ijnrd-4-017">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fismen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mortensen</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Rekvig</surname>
              <given-names>OP</given-names>
            </name>
          </person-group>
          <article-title>Nuclease deficiencies promote end-stage lupus nephritis but not nephritogenic autoimmunity in (NZBxNZW) F1 mice</article-title>
          <source>Immunol Cell Biol</source>
          <year>2010</year>
          <month>6</month>
          <day>15</day>
        </element-citation>
      </ref>
      <ref id="b52-ijnrd-4-017">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davis</surname>
              <given-names>JC</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Manzi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yarboro</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Recombinant human Dnase I (rhDNase) in patients with lupus nephritis</article-title>
          <source>Lupus</source>
          <year>1999</year>
          <volume>8</volume>
          <fpage>68</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="pmid">10025601</pub-id>
        </element-citation>
      </ref>
      <ref id="b53-ijnrd-4-017">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mistry-Burchardi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Schonermark</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Samtleben</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Apheresis in lupus nephritis</article-title>
          <source>Ther Apher</source>
          <year>2001</year>
          <volume>5</volume>
          <fpage>161</fpage>
          <lpage>170</lpage>
          <pub-id pub-id-type="pmid">11467751</pub-id>
        </element-citation>
      </ref>
      <ref id="b54-ijnrd-4-017">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamaji</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Tsuda</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term clinical outcomes of synchronized therapy with plasmapheresis and intravenous cyclophosphamide pulse therapy in the treatment of steroid-resistant lupus nephritis</article-title>
          <source>Ther Apher Dial</source>
          <year>2008</year>
          <volume>12</volume>
          <issue>4</issue>
          <fpage>298</fpage>
          <lpage>305</lpage>
          <pub-id pub-id-type="pmid">18789117</pub-id>
        </element-citation>
      </ref>
      <ref id="b55-ijnrd-4-017">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Danieli</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Palmieri</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Salvi</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis</article-title>
          <source>J Clin Apher</source>
          <year>2002</year>
          <volume>17</volume>
          <fpage>72</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="pmid">12210709</pub-id>
        </element-citation>
      </ref>
      <ref id="b56-ijnrd-4-017">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sugimoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yamaji</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>KS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis</article-title>
          <source>Ther Apher Dial</source>
          <year>2006</year>
          <volume>10</volume>
          <fpage>187</fpage>
          <lpage>192</lpage>
          <pub-id pub-id-type="pmid">16684222</pub-id>
        </element-citation>
      </ref>
      <ref id="b57-ijnrd-4-017">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takahashi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wada</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Harada</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Immunoadsorbent apheresis eliminates pathogenic IgG in childhood lupus nephritis</article-title>
          <source>Pediatr Int</source>
          <year>2007</year>
          <volume>49</volume>
          <fpage>817</fpage>
          <lpage>821</lpage>
          <pub-id pub-id-type="pmid">18045278</pub-id>
        </element-citation>
      </ref>
      <ref id="b58-ijnrd-4-017">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pascual</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Farkas</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Banchereau</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Systemic lupus erythematosus: all roads lead to type I interferons</article-title>
          <source>Curr Opin Immunol</source>
          <year>2006</year>
          <volume>18</volume>
          <fpage>676</fpage>
          <lpage>682</lpage>
          <pub-id pub-id-type="pmid">17011763</pub-id>
        </element-citation>
      </ref>
      <ref id="b59-ijnrd-4-017">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lafyatis</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>York</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marshak-Rothstein</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Antimalarial agents: closing the gate on Toll-like receptors?</article-title>
          <source>Arthritis Rheum</source>
          <year>2006</year>
          <volume>54</volume>
          <fpage>3068</fpage>
          <lpage>3070</lpage>
          <pub-id pub-id-type="pmid">17009223</pub-id>
        </element-citation>
      </ref>
      <ref id="b60-ijnrd-4-017">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fulmer</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Sparing steroids in lupus</article-title>
          <source>SciBX</source>
          <year>2010</year>
          <volume>3</volume>
          <fpage>1</fpage>
          <lpage>2</lpage>
        </element-citation>
      </ref>
      <ref id="b61-ijnrd-4-017">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Richman</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Higgs</surname>
              <given-names>BW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neutralizaiton of interferon-&#x3B1;/&#x3B2;-inducible genes and downstream effect in a phase I trial of an anti-inteferon-&#x3B1; monoclonal antibody in systemic lupus erythematosus</article-title>
          <source>Arthritis Rheum</source>
          <year>2009</year>
          <volume>60</volume>
          <fpage>1785</fpage>
          <lpage>1796</lpage>
          <pub-id pub-id-type="pmid">19479852</pub-id>
        </element-citation>
      </ref>
      <ref id="b62-ijnrd-4-017">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Madaio</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Carlson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cataldo</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits</article-title>
          <source>J Immunol</source>
          <year>1987</year>
          <volume>138</volume>
          <fpage>2883</fpage>
          <lpage>2889</lpage>
          <pub-id pub-id-type="pmid">3553329</pub-id>
        </element-citation>
      </ref>
      <ref id="b63-ijnrd-4-017">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>SK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mesangial cell-binding anti-DNA antibodies in patients with systemic lupus erythematosus</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2002</year>
          <volume>13</volume>
          <fpage>1219</fpage>
          <lpage>1229</lpage>
          <pub-id pub-id-type="pmid">11961009</pub-id>
        </element-citation>
      </ref>
      <ref id="b64-ijnrd-4-017">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Du</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cross-reaction of anti-DNA autoantibodies with membrane proteins of human glomerular mesangial cells in sera from patients with lupus nephritis</article-title>
          <source>Clin Exp Immunol</source>
          <year>2006</year>
          <volume>145</volume>
          <fpage>21</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="pmid">16792669</pub-id>
        </element-citation>
      </ref>
      <ref id="b65-ijnrd-4-017">
        <label>65.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kramers</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hylkema</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>van Bruggen</surname>
              <given-names>MCJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo</article-title>
          <source>J Clin Invest</source>
          <year>1994</year>
          <volume>94</volume>
          <fpage>568</fpage>
          <lpage>577</lpage>
          <pub-id pub-id-type="pmid">8040312</pub-id>
        </element-citation>
      </ref>
      <ref id="b66-ijnrd-4-017">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morioka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fujigaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Batsford</surname>
              <given-names>SR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-DNA antibody derived from a systemic lupus erythematosus (SLE) patient forms histone-DNA-anti-DNA complexes that bind to rat glomeruli in vivo</article-title>
          <source>Clin Exp Immunol</source>
          <year>1996</year>
          <volume>104</volume>
          <fpage>92</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="pmid">8603540</pub-id>
        </element-citation>
      </ref>
      <ref id="b67-ijnrd-4-017">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsao</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>Ohnishi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cheroutre</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Failed self-tolerance and autoimmunity in IgG anti-DNA transgenic mice</article-title>
          <source>J Immunol</source>
          <year>1992</year>
          <volume>149</volume>
          <fpage>350</fpage>
          <lpage>358</lpage>
          <pub-id pub-id-type="pmid">1607661</pub-id>
        </element-citation>
      </ref>
      <ref id="b68-ijnrd-4-017">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Brezis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rosenmann</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-DNA antibodies bind directly to renal antigens and induce kidney dysfunction in the isolated perfused rat kidney</article-title>
          <source>J Immunol</source>
          <year>1989</year>
          <volume>142</volume>
          <fpage>3076</fpage>
          <lpage>3082</lpage>
          <pub-id pub-id-type="pmid">2785132</pub-id>
        </element-citation>
      </ref>
      <ref id="b69-ijnrd-4-017">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ehrenstein</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Katz</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Griffiths</surname>
              <given-names>MH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice</article-title>
          <source>Kidney Int</source>
          <year>1995</year>
          <volume>48</volume>
          <fpage>705</fpage>
          <lpage>711</lpage>
          <pub-id pub-id-type="pmid">7474655</pub-id>
        </element-citation>
      </ref>
      <ref id="b70-ijnrd-4-017">
        <label>70.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ravirajan</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Rahman</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Papadaki</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis</article-title>
          <source>Eur J Immunol</source>
          <year>1998</year>
          <volume>28</volume>
          <fpage>339</fpage>
          <lpage>350</lpage>
          <pub-id pub-id-type="pmid">9485213</pub-id>
        </element-citation>
      </ref>
      <ref id="b71-ijnrd-4-017">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalaaji</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fenton</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Mortensen</surname>
              <given-names>ES</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis</article-title>
          <source>Kidney Int</source>
          <year>2007</year>
          <volume>71</volume>
          <fpage>664</fpage>
          <lpage>672</lpage>
          <pub-id pub-id-type="pmid">17332738</pub-id>
        </element-citation>
      </ref>
      <ref id="b72-ijnrd-4-017">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Casals</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Friou</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>LL</given-names>
            </name>
          </person-group>
          <article-title>Significance of antibody to DNA in systemic lupus erythematosus</article-title>
          <source>Arthritis Rheum</source>
          <year>1964</year>
          <volume>7</volume>
          <fpage>379</fpage>
          <lpage>390</lpage>
          <pub-id pub-id-type="pmid">14202576</pub-id>
        </element-citation>
      </ref>
      <ref id="b73-ijnrd-4-017">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cervera</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Vinas</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ramos-Casals</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy</article-title>
          <source>Ann Rheum Dis</source>
          <year>2003</year>
          <volume>62</volume>
          <fpage>431</fpage>
          <lpage>434</lpage>
          <pub-id pub-id-type="pmid">12695155</pub-id>
        </element-citation>
      </ref>
      <ref id="b74-ijnrd-4-017">
        <label>74.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>ter Borg</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Horst</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hummel</surname>
              <given-names>EJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: A long-term, prospective study</article-title>
          <source>Arthritis Rheum</source>
          <year>1990</year>
          <volume>33</volume>
          <issue>5</issue>
          <fpage>634</fpage>
          <lpage>643</lpage>
          <pub-id pub-id-type="pmid">2346519</pub-id>
        </element-citation>
      </ref>
      <ref id="b75-ijnrd-4-017">
        <label>75.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adler</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Baumgarten</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hecht</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Prognostic significance of DNA-binding capacity patterns in patients with lupus nephritis</article-title>
          <source>Ann Rheum Dis</source>
          <year>1975</year>
          <volume>34</volume>
          <fpage>444</fpage>
          <lpage>450</lpage>
          <pub-id pub-id-type="pmid">1221925</pub-id>
        </element-citation>
      </ref>
      <ref id="b76-ijnrd-4-017">
        <label>76.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Horowitz</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Furie</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Abetimus sodium: a medication for the prevention of lupus nephritis flares</article-title>
          <source>Expert Opin Pharmacother</source>
          <year>2009</year>
          <volume>10</volume>
          <fpage>1501</fpage>
          <lpage>1507</lpage>
          <pub-id pub-id-type="pmid">19505217</pub-id>
        </element-citation>
      </ref>
      <ref id="b77-ijnrd-4-017">
        <label>77.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Donadio</surname>
              <given-names>JVJ</given-names>
            </name>
            <name>
              <surname>Holley</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Ferguson</surname>
              <given-names>RH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide</article-title>
          <source>N Engl J Med</source>
          <year>1978</year>
          <volume>299</volume>
          <fpage>1151</fpage>
          <lpage>1155</lpage>
          <pub-id pub-id-type="pmid">309095</pub-id>
        </element-citation>
      </ref>
      <ref id="b78-ijnrd-4-017">
        <label>78.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Houssiau</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Vasconcelos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>D&#x2019;Cruz</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide</article-title>
          <source>Arthritis Rheum</source>
          <year>2002</year>
          <volume>46</volume>
          <fpage>2121</fpage>
          <lpage>2131</lpage>
          <pub-id pub-id-type="pmid">12209517</pub-id>
        </element-citation>
      </ref>
      <ref id="b79-ijnrd-4-017">
        <label>79.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Houssiau</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Vasconcelos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>D&#x2019;Cruz</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide</article-title>
          <source>Ann Rheum Dis</source>
          <year>2010</year>
          <volume>69</volume>
          <fpage>61</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="pmid">19155235</pub-id>
        </element-citation>
      </ref>
      <ref id="b80-ijnrd-4-017">
        <label>80.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brodsky</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>RJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial</article-title>
          <source>Arthritis Rheum</source>
          <year>2010</year>
          <volume>62</volume>
          <fpage>1487</fpage>
          <lpage>1493</lpage>
          <pub-id pub-id-type="pmid">20131296</pub-id>
        </element-citation>
      </ref>
      <ref id="b81-ijnrd-4-017">
        <label>81.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yee</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dostal</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2003</year>
          <volume>63</volume>
          <fpage>525</fpage>
          <lpage>529</lpage>
          <pub-id pub-id-type="pmid">15082482</pub-id>
        </element-citation>
      </ref>
      <ref id="b82-ijnrd-4-017">
        <label>82.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Illei</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Yarboro</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Kuroiwa</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2007</year>
          <volume>46</volume>
          <fpage>952</fpage>
          <lpage>956</lpage>
          <pub-id pub-id-type="pmid">17317716</pub-id>
        </element-citation>
      </ref>
      <ref id="b83-ijnrd-4-017">
        <label>83.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ginzler</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Dooley</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Aranow</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>353</volume>
          <fpage>2219</fpage>
          <lpage>2228</lpage>
          <pub-id pub-id-type="pmid">16306519</pub-id>
        </element-citation>
      </ref>
      <ref id="b84-ijnrd-4-017">
        <label>84.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Appel</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Contreras</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dooley</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2009</year>
          <volume>20</volume>
          <fpage>1103</fpage>
          <lpage>1112</lpage>
          <pub-id pub-id-type="pmid">19369404</pub-id>
        </element-citation>
      </ref>
      <ref id="b85-ijnrd-4-017">
        <label>85.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Radhakrishnan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moutzouris</surname>
              <given-names>D-A</given-names>
            </name>
            <name>
              <surname>Ginzler</surname>
              <given-names>EM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis</article-title>
          <source>Kidney Int</source>
          <year>2010</year>
          <volume>77</volume>
          <fpage>152</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="pmid">19890271</pub-id>
        </element-citation>
      </ref>
      <ref id="b86-ijnrd-4-017">
        <label>86.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ong</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Hooi</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>TO</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis</article-title>
          <source>Nephrology</source>
          <year>2005</year>
          <volume>10</volume>
          <fpage>504</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="pmid">16221103</pub-id>
        </element-citation>
      </ref>
      <ref id="b87-ijnrd-4-017">
        <label>87.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials</article-title>
          <source>Nephrol Dial Transplant</source>
          <year>2007</year>
          <volume>22</volume>
          <fpage>1933</fpage>
          <lpage>1942</lpage>
          <pub-id pub-id-type="pmid">17405792</pub-id>
        </element-citation>
      </ref>
      <ref id="b88-ijnrd-4-017">
        <label>88.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lanata</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Mahmood</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fine</surname>
              <given-names>DM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis</article-title>
          <source>Lupus</source>
          <year>2010</year>
          <volume>19</volume>
          <fpage>935</fpage>
          <lpage>940</lpage>
          <pub-id pub-id-type="pmid">20388722</pub-id>
        </element-citation>
      </ref>
      <ref id="b89-ijnrd-4-017">
        <label>89.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grootscholten</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ligtenberg</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hagen</surname>
              <given-names>EC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial</article-title>
          <source>Kidney Int</source>
          <year>2006</year>
          <volume>70</volume>
          <fpage>732</fpage>
          <lpage>742</lpage>
          <pub-id pub-id-type="pmid">16820790</pub-id>
        </element-citation>
      </ref>
      <ref id="b90-ijnrd-4-017">
        <label>90.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grootscholten</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bajema</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Florquin</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis</article-title>
          <source>Arthritis Rheum</source>
          <year>2007</year>
          <volume>56</volume>
          <fpage>924</fpage>
          <lpage>937</lpage>
          <pub-id pub-id-type="pmid">17328070</pub-id>
        </element-citation>
      </ref>
      <ref id="b91-ijnrd-4-017">
        <label>91.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>TM</given-names>
            </name>
          </person-group>
          <article-title>Histologic deterioration and more flares: the case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis</article-title>
          <source>Arthritis Rheum</source>
          <year>2007</year>
          <volume>56</volume>
          <fpage>702</fpage>
          <lpage>704</lpage>
          <pub-id pub-id-type="pmid">17328038</pub-id>
        </element-citation>
      </ref>
      <ref id="b92-ijnrd-4-017">
        <label>92.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zavada</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pesickova</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rysava</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study</article-title>
          <source>Lupus</source>
          <year>2010</year>
          <volume>19</volume>
          <fpage>1281</fpage>
          <lpage>1289</lpage>
          <pub-id pub-id-type="pmid">20605876</pub-id>
        </element-citation>
      </ref>
      <ref id="b93-ijnrd-4-017">
        <label>93.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramos-Casals</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Soto</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Cuadrado</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases</article-title>
          <source>Lupus</source>
          <year>2009</year>
          <volume>18</volume>
          <fpage>767</fpage>
          <lpage>776</lpage>
          <pub-id pub-id-type="pmid">19578100</pub-id>
        </element-citation>
      </ref>
      <ref id="b94-ijnrd-4-017">
        <label>94.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>Tam</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>TY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2009</year>
          <volume>48</volume>
          <fpage>892</fpage>
          <lpage>898</lpage>
          <pub-id pub-id-type="pmid">19478041</pub-id>
        </element-citation>
      </ref>
      <ref id="b95-ijnrd-4-017">
        <label>95.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lateef</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lahiri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Teng</surname>
              <given-names>GG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience</article-title>
          <source>Lupus</source>
          <year>2010</year>
          <volume>19</volume>
          <fpage>765</fpage>
          <lpage>770</lpage>
          <pub-id pub-id-type="pmid">20118162</pub-id>
        </element-citation>
      </ref>
      <ref id="b96-ijnrd-4-017">
        <label>96.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia-Carrasco</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mendoza-Pinto</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sandoval-Cruz</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients</article-title>
          <source>Lupus</source>
          <year>2010</year>
          <volume>19</volume>
          <fpage>213</fpage>
          <lpage>219</lpage>
          <pub-id pub-id-type="pmid">19965944</pub-id>
        </element-citation>
      </ref>
      <ref id="b97-ijnrd-4-017">
        <label>97.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jonsdottir</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gunnarsson</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mourao</surname>
              <given-names>AF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2010</year>
          <volume>49</volume>
          <fpage>1502</fpage>
          <lpage>1504</lpage>
          <pub-id pub-id-type="pmid">20427294</pub-id>
        </element-citation>
      </ref>
      <ref id="b98-ijnrd-4-017">
        <label>98.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Contreras</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pardo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Leclercq</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sequential therapies for proliferative lupus nephritis</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>350</volume>
          <fpage>971</fpage>
          <lpage>980</lpage>
          <pub-id pub-id-type="pmid">14999109</pub-id>
        </element-citation>
      </ref>
      <ref id="b99-ijnrd-4-017">
        <label>99.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Contreras</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tozman</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nahar</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide</article-title>
          <source>Lupus</source>
          <year>2005</year>
          <volume>14</volume>
          <fpage>s33</fpage>
          <lpage>s38</lpage>
          <pub-id pub-id-type="pmid">15803929</pub-id>
        </element-citation>
      </ref>
      <ref id="b100-ijnrd-4-017">
        <label>100.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sahin</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Sahin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kiziltas</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis</article-title>
          <source>Renal Failure</source>
          <year>2008</year>
          <volume>30</volume>
          <fpage>865</fpage>
          <lpage>869</lpage>
          <pub-id pub-id-type="pmid">18925525</pub-id>
        </element-citation>
      </ref>
      <ref id="b101-ijnrd-4-017">
        <label>101.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Houssiau</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>D&#x2019;Cruz</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sangle</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
            <collab>the MAINTAIN Nephritis Trial Group</collab>
          </person-group>
          <article-title>Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial</article-title>
          <source>Ann Rheum Dis</source>
          <year>2010</year>
          <volume>69</volume>
          <fpage>2083</fpage>
          <lpage>2089</lpage>
          <pub-id pub-id-type="pmid">20833738</pub-id>
        </element-citation>
      </ref>
      <ref id="b102-ijnrd-4-017">
        <label>102.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wofsy</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Appel</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Dooley</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Aspreva Lupus Management Study maintenance results</article-title>
          <source>Lupus</source>
          <year>2010</year>
          <volume>19</volume>
          <issue>Suppl</issue>
          <fpage>27</fpage>
          <comment>(CS12.6).</comment>
          <pub-id pub-id-type="pmid">19933722</pub-id>
        </element-citation>
      </ref>
      <ref id="b103-ijnrd-4-017">
        <label>103.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moroni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Doria</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mosca</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years</article-title>
          <source>Clin J Am Soc Nephrol</source>
          <year>2006</year>
          <volume>1</volume>
          <fpage>925</fpage>
          <lpage>932</lpage>
          <pub-id pub-id-type="pmid">17699309</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f1-ijnrd-4-017" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Model of DNA-anti-DNA immune complex generation and glomerular damage in lupus nephritis and potential therapeutic targets.</p>
        <p><bold>Abbreviations:</bold> Abs, antibodies; DCs, dendritic cells; GC, germinal center; ICs, immune complexes; RBCs, red blood cells; RES, reticuloendothelial system.</p>
      </caption>
      <graphic xlink:href="ijnrd-4-017f1"/>
    </fig>
    <table-wrap id="t1-ijnrd-4-017" position="float">
      <label>Table 1</label>
      <caption>
        <p>Classification of lupus nephritis</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="middle" rowspan="1" colspan="1">
              <bold>Class</bold>
            </th>
            <th align="left" valign="middle" rowspan="1" colspan="1">
              <bold>WHO (1982)</bold>
            </th>
            <th align="left" valign="middle" rowspan="1" colspan="1">
              <bold>ISN/RPS<xref ref-type="table-fn" rid="tfn3-ijnrd-4-017"><sup>b</sup></xref> (2003)</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">I</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Normal glomeruli
<list list-type="alpha-lower"><list-item><p>Nil by all techniques</p></list-item><list-item><p>Normal LM, deposits by EM/IF</p></list-item></list></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Minimal mesangial
<list list-type="bullet"><list-item><p>Normal LM. Deposits by IF &#xB1; EM. No longer includes those with normal IF/EM</p></list-item></list></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">II</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Pure mesangial
<list list-type="alpha-lower"><list-item><p>Mesangial widening or hypercellularity</p></list-item><list-item><p>Moderate hypercellularity</p></list-item></list></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Mesangial proliferative</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">III</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Focal segmental<xref ref-type="table-fn" rid="tfn2-ijnrd-4-017"><sup>a</sup></xref><list list-type="alpha-lower"><list-item><p>&#x2018;Active&#x2019; necrotizing lesions</p></list-item><list-item><p>&#x2018;Active&#x2019; and sclerosing lesions</p></list-item><list-item><p>Sclerosing lesions</p></list-item></list></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Focal (&lt;50% glomeruli)<xref ref-type="table-fn" rid="tfn4-ijnrd-4-017"><sup>c</sup></xref><break/>A. Active lesions<break/>A/C. Active and chronic lesions<break/>C. Chronic inactive lesions with scars</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IV</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Diffuse<xref ref-type="table-fn" rid="tfn2-ijnrd-4-017"><sup>a</sup></xref><list list-type="alpha-lower"><list-item><p>Without segmental lesions</p></list-item><list-item><p>&#x2018;Active&#x2019; necrotizing lesions</p></list-item><list-item><p>&#x2018;Active&#x2019; and sclerosing lesions</p></list-item><list-item><p>Sclerosing lesions</p></list-item></list></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Diffuse segmental (IV-S) or global (IV-G)<xref ref-type="table-fn" rid="tfn5-ijnrd-4-017"><sup>d</sup></xref> (&#x2265;50% glomeruli segmental or global lesions). A, A/C, C as above</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">V</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Diffuse membranous
<list list-type="alpha-lower"><list-item><p>Pure membranous</p></list-item><list-item><p>Assoc class IIa/b lesions</p></list-item><list-item><p>Assoc class IIIa-c lesions</p></list-item><list-item><p>Assoc class IVa-d lesions</p></list-item></list></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Membranous<break/>May occur in combination with class III or IV, in which case both will be diagnosed</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">VI</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Advanced sclerosing<xref ref-type="table-fn" rid="tfn2-ijnrd-4-017"><sup>a</sup></xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Advanced sclerosing (&#x2265;90% of glomeruli globally sclerosed without residual activity)</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tfn1-ijnrd-4-017">
          <p>
            <bold>Notes:</bold>
          </p>
        </fn>
        <fn id="tfn2-ijnrd-4-017">
          <label>a</label>
          <p>Percentage was not stipulated in the 1982 modification of the WHO criteria;</p>
        </fn>
        <fn id="tfn3-ijnrd-4-017">
          <label>b</label>
          <p>Indicate and grade (mild, moderate, severe) tubular atrophy, interstitial inflammation and fibrosis, severity of arteriosclerosis or other vascular lesions;</p>
        </fn>
        <fn id="tfn4-ijnrd-4-017">
          <label>c</label>
          <p>Indicate the proportion of glomeruli with active and with sclerotic lesions;</p>
        </fn>
        <fn id="tfn5-ijnrd-4-017">
          <label>d</label>
          <p>Indicate the proportion of glomeruli with fibrinoid necrosis and cellular crescents.</p>
        </fn>
        <fn id="tfn6-ijnrd-4-017">
          <p><bold>Abbreviations:</bold> EM, electron microscopy; IF, immunofluorescence; ISN/RPS, International Society of Nephrology/Renal Pathology Society; LM, light microscopy; WHO, World Health Organization.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="t2-ijnrd-4-017" position="float">
      <label>Table 2</label>
      <caption>
        <p>Evidence for role of DNA-containing immune complexes in the pathogenesis of lupus nephritis</p>
      </caption>
      <table frame="hsides" rules="groups">
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Murine models</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <list list-type="bullet">
                <list-item>
                  <p>Anti-DNA antibodies bind directly to non-DNA antigenic structures in normal glomeruli<xref ref-type="bibr" rid="b62-ijnrd-4-017">62</xref>&#x2013;<xref ref-type="bibr" rid="b64-ijnrd-4-017">64</xref></p>
                </list-item>
                <list-item>
                  <p>Immune complexes containing nucleosomes/DNA bind to glomerular basement membranes<xref ref-type="bibr" rid="b65-ijnrd-4-017">65</xref> and glomerular capillary walls.<xref ref-type="bibr" rid="b66-ijnrd-4-017">66</xref> These might serve to localize antibody-mediated injury to the glomerulus. Co-deposition of C3 complement suggests that these antibodies might initiate complement-mediated damage<xref ref-type="bibr" rid="b65-ijnrd-4-017">65</xref></p>
                </list-item>
                <list-item>
                  <p>Transgenic mice expressing anti-DNA antibodies who are not otherwise predisposed to develop lupus, develop nephritis<xref ref-type="bibr" rid="b67-ijnrd-4-017">67</xref></p>
                </list-item>
                <list-item>
                  <p>Infusion or transfer of anti-DNA antibodies causes nephritis<xref ref-type="bibr" rid="b68-ijnrd-4-017">68</xref>&#x2013;<xref ref-type="bibr" rid="b70-ijnrd-4-017">70</xref></p>
                </list-item>
              </list>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human studies</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <list list-type="bullet">
                <list-item>
                  <p>Chromatin colocalises with autoantibodies in glomerular-membrane-associated electron dense structures in nephritic kidneys<xref ref-type="bibr" rid="b71-ijnrd-4-017">71</xref></p>
                </list-item>
                <list-item>
                  <p>Correlation between presence<xref ref-type="bibr" rid="b11-ijnrd-4-017">11</xref>,<xref ref-type="bibr" rid="b72-ijnrd-4-017">72</xref>,<xref ref-type="bibr" rid="b73-ijnrd-4-017">73</xref> and increasing levels<xref ref-type="bibr" rid="b74-ijnrd-4-017">74</xref> of anti-dsDNA antibodies and lupus nephritis</p>
                </list-item>
                <list-item>
                  <p>Correlation between presence of antinucleosome antibodies and lupus nephritis<xref ref-type="bibr" rid="b73-ijnrd-4-017">73</xref></p>
                </list-item>
                <list-item>
                  <p>Persistently high titers of anti-dsDNA antibodies are a poor prognostic factor in proliferative lupus nephritis<xref ref-type="bibr" rid="b75-ijnrd-4-017">75</xref></p>
                </list-item>
                <list-item>
                  <p>Patients with sustained reductions in anti-dsDNA antibodies 5&#x2013;7 &#xD7; less likely to have nephritic flares in a study of treatment with abetimus<xref ref-type="bibr" rid="b76-ijnrd-4-017">76</xref></p>
                </list-item>
              </list>
            </td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="t3-ijnrd-4-017" position="float">
      <label>Table 3</label>
      <caption>
        <p>Trials of induction therapies for lupus nephritis</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Class of nephritis<xref ref-type="bibr" rid="b5-ijnrd-4-017">5</xref></bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Study design</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Intervention 1</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Intervention 2</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Number of LN patients (intervention 1 vs 2)</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Duration of follow-up</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Outcome</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Reference</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" colspan="2" rowspan="1">
              <bold>Trials of various cyclophosphamide regimens</bold>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">IV</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Prednisone (av 40 mg/d).<break/>Maintenance prednisone</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Prednisone (av 29 mg/day) plus PO CYC (average 107 mg/day) for 6 months. Maintenance prednisone</td>
            <td align="left" valign="top" rowspan="1" colspan="1">26 vs 24</td>
            <td align="left" valign="top" rowspan="1" colspan="1">4 years</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Lower relapse rate in PO CYC group (48% vs 14%) with steroid sparing effect of PO CYC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Donadio et al<xref ref-type="bibr" rid="b77-ijnrd-4-017">77</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">WHO III, IV, Vc, Vd</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">IV CYC 0.5 g/m<sup>2</sup> monthly (increased acc to nadir WBC to max 1.5 g) for 6 months followed by 2 quarterly pulses. AZA 2 weeks after last CYC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Low dose IV CYC: 500 mg fortnightly &#xD7; 6 doses. AZA 2 weeks after last CYC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">46 vs 44</td>
            <td align="left" valign="top" rowspan="1" colspan="1">10 years</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Similar outcomes for renal remissions, renal flares, death, doubling of creatinine (12%), ESRD (7%)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Houssiau et al (Euro-Lupus Nephritis Trial)<xref ref-type="bibr" rid="b78-ijnrd-4-017">78</xref>,<xref ref-type="bibr" rid="b79-ijnrd-4-017">79</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Not classified</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Monthly IV CYC 750 mg/m<sup>2</sup> for 6 months followed by quarterly IV CYC for 2 years</td>
            <td align="left" valign="top" rowspan="1" colspan="1">High dose (50 mg/kg) IV CYC for 4 days</td>
            <td align="left" valign="top" rowspan="1" colspan="1">26 vs 21</td>
            <td align="left" valign="top" rowspan="1" colspan="1">30 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">64% vs 20% complete renal response (<italic>P</italic> = 0.08)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Petri et al<xref ref-type="bibr" rid="b80-ijnrd-4-017">80</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Proliferative</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">IV CYC 10 mg/kg every 3 weeks for 4 doses. Then PO CYC 5 mg/kg for 2 days every 4 weeks for 9 months; then every 6 weeks for 12 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">PO CYC 2 mg/kg/day for 3 months then AZA 1.5 mg/kg/day</td>
            <td align="left" valign="top" rowspan="1" colspan="1">16 vs 16</td>
            <td align="left" valign="top" rowspan="1" colspan="1">3.3 years</td>
            <td align="left" valign="top" rowspan="1" colspan="1">No difference in efficacy</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Yee et al<xref ref-type="bibr" rid="b81-ijnrd-4-017">81</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Proliferative</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Phase I/II pilot study</td>
            <td align="left" valign="top" rowspan="1" colspan="1">PO CYC 0.5 g/m<sup>2</sup> BSA monthly with SC fludarabine 30 mg/m<sup>2</sup> on days 1&#x2013;3 for 3&#x2013;6 cycles</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">13</td>
            <td align="left" valign="top" rowspan="1" colspan="1">2.6 to 6.7 years</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Severe myelosuppression &#x2013; study terminated</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Illei et al<xref ref-type="bibr" rid="b82-ijnrd-4-017">82</xref></td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" rowspan="1">
              <bold>Trials of mycophenolate vs IV cyclophosphamide</bold>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">V</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Pooled analysis of pure class V nephritis from two studies<xref ref-type="bibr" rid="b83-ijnrd-4-017">83</xref>,<xref ref-type="bibr" rid="b84-ijnrd-4-017">84</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">MMF 2.5&#x2013;3.0 g/day</td>
            <td align="left" valign="top" rowspan="1" colspan="1">IV CYC as per NIH protocol</td>
            <td align="left" valign="top" rowspan="1" colspan="1">42 vs 42</td>
            <td align="left" valign="top" rowspan="1" colspan="1">6 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Similar outcomes for urine protein, change in urine protein, complete and partial remission rates</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Radhakrishnan et al<xref ref-type="bibr" rid="b85-ijnrd-4-017">85</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">III, IV or V</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MMF target dose 3 g/d</td>
            <td align="left" valign="top" rowspan="1" colspan="1">IV CYC NIH protocol; median dose received 0.75 g/m<sup>2</sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">185 vs 185</td>
            <td align="left" valign="top" rowspan="1" colspan="1">24 weeks, maintenance phase reported below</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Similar response rate (56% vs 53%)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Appel et al (ALMS group)<xref ref-type="bibr" rid="b84-ijnrd-4-017">84</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">III, IV or V</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Meta-analysis of Ginzler 2005<xref ref-type="bibr" rid="b83-ijnrd-4-017">83</xref> and Ong 2005<xref ref-type="bibr" rid="b86-ijnrd-4-017">86</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">MMF 1 g bid for 6 months<xref ref-type="bibr" rid="b86-ijnrd-4-017">86</xref>. MMF pushed up to 3 g daily if tolerated<xref ref-type="bibr" rid="b83-ijnrd-4-017">83</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">IV CYC 0.75&#x2013;1.0 g/m<sup>2</sup> monthly for 6 months.<xref ref-type="bibr" rid="b86-ijnrd-4-017">86</xref> NIH IV CYC<xref ref-type="bibr" rid="b83-ijnrd-4-017">83</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">90 vs 94</td>
            <td align="left" valign="top" rowspan="1" colspan="1">6 months<xref ref-type="bibr" rid="b86-ijnrd-4-017">86</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Complete remission rate after induction therapy higher in MMF group</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Zhu et al<xref ref-type="bibr" rid="b87-ijnrd-4-017">87</xref></td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" rowspan="1">
              <bold>Miscellaneous trials of conventional immunosuppressant agents</bold>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Various</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Retrospective review of Hopkins Lupus Cohort</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addition of tacrolimus to MMF in those failing MMF</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">7</td>
            <td align="left" valign="top" rowspan="1" colspan="1">2&#x2013;54 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Frequent toxicity, infrequent success (1 patient achieved complete renal remission)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Lanata et al<xref ref-type="bibr" rid="b88-ijnrd-4-017">88</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">WHO III, IV, Vc, Vd</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">AZA 2 mg/kg/day and pulse MP (3 &#xD7; 3 pulses of 1 g over 2 years)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">IV CYC 750 mg/m<sup>2</sup> (13 doses over 2 years)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">37 vs 50</td>
            <td align="left" valign="top" rowspan="1" colspan="1">5.7 years</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Relapses more frequent in AZA group (RR8.8). Higher chronicity and activity indices on repeat biopsy in AZA group</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Grootscholten (Dutch Working Party on SLE)<xref ref-type="bibr" rid="b89-ijnrd-4-017">89</xref>,<xref ref-type="bibr" rid="b90-ijnrd-4-017">90</xref>; Chan<xref ref-type="bibr" rid="b91-ijnrd-4-017">91</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">III or IV</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">CSA 4&#x2013;5 mg/kg/d for 9 months, gradually decreasing (3.75&#x2013;1.25 mg/kg/d) over next 9 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">IV CYC 8 doses of 10 mg/kg IV over 9 months, then 4&#x2013;5 &#xD7; PO at same dose ever 6&#x2013;8 weeks</td>
            <td align="left" valign="top" rowspan="1" colspan="1">19 vs 21</td>
            <td align="left" valign="top" rowspan="1" colspan="1">18 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">CSA as effective as CYC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Zavada et al (Cyclofa-Lune study)<xref ref-type="bibr" rid="b92-ijnrd-4-017">92</xref></td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" rowspan="1">
              <bold>Trials of rituximab</bold>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">III, IV, V</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Systematic review including 9 uncontrolled studies and 26 case reports (not including other papers listed in this table)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Various regimens of RTX. 52% had concomitant IV CYC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">103 with lupus nephritis (188 SLE in total)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">17 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Renal response 91%. CRR 67%, PRR 33%. Higher response rate in those having concomitant CYC than those who did not. Lymphoma regimen (375 mg/m<sup>2</sup> &#xD7; 4 doses) appeared more effective</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Ramos-Casals et al<xref ref-type="bibr" rid="b93-ijnrd-4-017">93</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">III or IV</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RTX monotherapy. 1000 mg IV 2 doses 2 weeks apart</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RTX + IV CYC. As for group1 but with IV CYC 750 mg following the first dose of RTX</td>
            <td align="left" valign="top" rowspan="1" colspan="1">9 vs 10</td>
            <td align="left" valign="top" rowspan="1" colspan="1">48 weeks</td>
            <td align="left" valign="top" rowspan="1" colspan="1">No difference in CRR (21%) or PRR (58%).<break/>Rituximab effective as induction therapy</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Li et al<xref ref-type="bibr" rid="b94-ijnrd-4-017">94</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">WHO IV or V</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Retrospective study of refractory LN</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RTX 375 mg/m<sup>2</sup> 2 doses 2 weeks apart accompanied by IV CYC 500 mg each time</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">7 with refractory LN</td>
            <td align="left" valign="top" rowspan="1" colspan="1">18 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">3/7 had CRR, 4/7 had PRR. Most had disease flares 6&#x2013;12 months after B cell repopulation</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Lateef et al<xref ref-type="bibr" rid="b95-ijnrd-4-017">95</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">WHO III or IV (not all biopsied)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Observational</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RTX 1000 mg days 1 and 15. Added to current immunosuppressive treatment</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">13 Hispanic with active lupus nephritis</td>
            <td align="left" valign="top" rowspan="1" colspan="1">6 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">38% CRR, 38% PRR</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Garcia-Carrasco et al<xref ref-type="bibr" rid="b96-ijnrd-4-017">96</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">WHO III&#x2013;V</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RTX 275 mg/m<sup>2</sup> weekly for 4 doses; IV CYC 500&#x2013;100 mg 3 weeks apart for 2 doses</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">28 (WHO III and IV) and 15 (WHO V)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">12 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Membranous and proliferative LN respond similarly to rituximab</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Jonsdottir et al<xref ref-type="bibr" rid="b97-ijnrd-4-017">97</xref></td>
          </tr>
          <tr>
            <td colspan="8" align="left" valign="top" rowspan="1">
              <hr/>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">ISN III or IV</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RDBPCT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RTX 1000 mg on days 1 and 15; repeated at 6 months. Background MMF target dose 3 g/day</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Placebo + MMF target dose 3 g/day</td>
            <td align="left" valign="top" rowspan="1" colspan="1">72 vs 72</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">No difference in renal response despite better serological response in rituximab group</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Furie et al (LUNAR)<xref ref-type="bibr" rid="b33-ijnrd-4-017">33</xref>; Looney<xref ref-type="bibr" rid="b34-ijnrd-4-017">34</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">ISN III-V</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Prospective observational registry</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RTX, various protocols</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2013;</td>
            <td align="left" valign="top" rowspan="1" colspan="1">42</td>
            <td align="left" valign="top" rowspan="1" colspan="1">&gt;3 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">CRR in 45%, PRR in 29% (total renal response rate 74%)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Terrier et al (French AutoImmunity and Rituximab Registry)<xref ref-type="bibr" rid="b36-ijnrd-4-017">36</xref></td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tfn7-ijnrd-4-017">
          <p><bold>Note:</bold> All studies are with corticosteroids in both arms, unless specified.</p>
        </fn>
        <fn id="tfn8-ijnrd-4-017">
          <p><bold>Abbreviations:</bold> AZA, azathioprine; bid, twice daily; CRF, chronic renal failure; CRR, complete renal response; CSA, cyclosporine A; CYC, cyclophosphamide; ESRD, end stage renal disease; IV, intravenous; LN, lupus nephritis; MMF, mycophenolate mofetil; PO, per oral; PRR, partial renal response; RCT, randomized controlled trial; RDBPCT, randomized double-blinded placebo-controlled trial; RTX, rituximab.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="t4-ijnrd-4-017" position="float">
      <label>Table 4</label>
      <caption>
        <p>Trials of maintenance therapies in lupus nephritis. All received glucocorticoids unless otherwise specified</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Class of nephritis<xref ref-type="bibr" rid="b5-ijnrd-4-017">5</xref></bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Study design</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Induction</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Maintenance strategy 1</bold>
            </th>
            <th colspan="2" align="left" valign="top" rowspan="1">
              <bold>Maintenance strategy 2</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Number of LN patients (strategy 1 vs 2 vs 3)</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Duration of follow-up</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Outcome</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Reference</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">WHO III, IV, Vb</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">IV CYC 0.5&#x2013;1.0 g/m<sup>2</sup> monthly for 7 doses</td>
            <td align="left" valign="top" rowspan="1" colspan="1">AZA 1&#x2013;3 mg/kg day</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MMF 1.5 g/day for 12 months then weaned</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Maintenance strategy 3: IV CYC 0.5&#x2013;1.0 g/m<sup>2</sup> every 3 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">19 vs 20 vs 20</td>
            <td align="left" valign="top" rowspan="1" colspan="1">72 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Relapse free survival highest in MMF group (77%) vs AZA (57%) and IV CYC (43%). MMF and AZA better for composite endpoint of death or CRF</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Contreras et al<xref ref-type="bibr" rid="b98-ijnrd-4-017">98</xref>,<xref ref-type="bibr" rid="b99-ijnrd-4-017">99</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">III&#x2013;V</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Retrospective study</td>
            <td align="left" valign="top" rowspan="1" colspan="1">IV CYC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">AZA 2 mg/kg/day</td>
            <td colspan="2" align="left" valign="top" rowspan="1">MMF 1.5&#x2013;2.0 g/day</td>
            <td align="left" valign="top" rowspan="1" colspan="1">15 vs 17</td>
            <td align="left" valign="top" rowspan="1" colspan="1">41 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">CRR similar (60% vs 58%)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Sahin et al<xref ref-type="bibr" rid="b100-ijnrd-4-017">100</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Proliferative</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Eurolupus IV CYC (500 mg &#xD7; 6 fortnightly doses). Maintenance Rx started at week 12. Renal response not required prior to commencing maintenance</td>
            <td align="left" valign="top" rowspan="1" colspan="1">AZA 2 mg/kg/day target dose</td>
            <td colspan="2" align="left" valign="top" rowspan="1">MMF 2 g/day target dose</td>
            <td align="left" valign="top" rowspan="1" colspan="1">52 vs 53</td>
            <td align="left" valign="top" rowspan="1" colspan="1">14 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Renal relapse rate similar (25% vs 19%)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Houssiau et al (MAINTAIN trial)<xref ref-type="bibr" rid="b101-ijnrd-4-017">101</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">III&#x2013;V</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RDBPCT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MMF vs IV CYC. Patients who achieved partial or complete response re-randomized at week 24</td>
            <td align="left" valign="top" rowspan="1" colspan="1">AZA 2 mg/kg/day</td>
            <td colspan="2" align="left" valign="top" rowspan="1">MMF 2 g/day</td>
            <td align="left" valign="top" rowspan="1" colspan="1">227</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Not yet published in full</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MMF superior to AZA in delaying time to treatment failure (composite of death, serious renal damage, renal relapse)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Wofsy et al (ALMS group)<xref ref-type="bibr" rid="b102-ijnrd-4-017">102</xref></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">WHO IV,Vc,Vd</td>
            <td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">PO CYC 1&#x2013;2 mg/kg/day for 3 months</td>
            <td align="left" valign="top" rowspan="1" colspan="1">AZA 2 mg/kg/day for 1 month then optional reduction to 1.5 mg/kg/day if well controlled</td>
            <td colspan="2" align="left" valign="top" rowspan="1">CSA 4 mg/kg/day for 1 month then weaned to 2.5&#x2013;3.0 mg/kg/day keeping trough level of 75&#x2013;200 ng/mL</td>
            <td align="left" valign="top" rowspan="1" colspan="1">33 vs 36</td>
            <td align="left" valign="top" rowspan="1" colspan="1">4 years</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Similar rates of SLE flare (13.4 vs 10.6 flares per 100 patient years), proteinuria and creatinine clearance</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Moroni et al<xref ref-type="bibr" rid="b103-ijnrd-4-017">103</xref></td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tfn9-ijnrd-4-017">
          <p><bold>Abbreviations:</bold> see <xref ref-type="table" rid="t3-ijnrd-4-017">Table 3</xref>.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
